Safety and Efficacy of Durvalumab After Chemoradiotherapy in Antinuclear Antibody-positive Patients With Non-small Cell Lung Cancer
ANA-positive patients receiving durvalumab after CRT tended to have a higher frequency of severe pneumonitis and significantly worse PFS and OS compared with ANA-negative patients.
Authors
- Kyoichi Okishio (ORCID: https://orcid.org/0000-0002-6348-1302)
- Yuji Inagaki (ORCID: https://orcid.org/0000-0002-2208-9478)
- Yoshihiko Taniguchi (ORCID: https://orcid.org/0000-0001-6387-3683)
- Akihiro Tamiya (ORCID: https://orcid.org/0000-0003-3599-2583)
- Yoshinobu Matsuda (ORCID: https://orcid.org/0000-0001-5092-9377)
- Akihiro Tsukaguchi (ORCID: https://orcid.org/0009-0009-6296-4386)
- Kensuke Kanaoka (ORCID: https://orcid.org/0000-0002-1266-7043)
- Yuya Tanaka (ORCID: https://orcid.org/0000-0002-5844-1904)
- Keiko Nakao
- Shoichi Fukuda
- Tomoko Kagawa
- Yuki Iwahashi
Institutions
- NHO Kinki Chuo Chest Medical Center (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-09-30
- DOI
- https://doi.org/10.21873/anticanres.17280
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00